L T & L Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 16-12-2024
- Paid Up Capital ₹ 0.10 M
as on 16-12-2024
- Company Age 11 Year, 1 Month
- Last Filing with ROC 31 Mar 2017
- Open Charges ₹ 1.00 Cr
as on 16-12-2024
- Revenue 210.34%
(FY 2016)
- Profit -113.82%
(FY 2016)
- Ebitda -108.82%
(FY 2016)
- Net Worth -443.57%
(FY 2016)
- Total Assets 69.26%
(FY 2016)
About L T & L Pharma
The Corporate was formerly known as Jaydev Bio Organic Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2017. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.00 Cr.
Pareshkumar Prajapati, Jayesh Bheraji, Chunilal Prajapati, and One other member serve as directors at the Company.
- CIN/LLPIN
U01132GJ2013PTC077595
- Company No.
077595
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Nov 2013
- Date of AGM
20 Jun 2017
- Date of Balance Sheet
31 Mar 2017
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at L T & L Pharma?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pareshkumar Prajapati  | Director | 20-Nov-2014 | Current |
| Jayesh Bheraji | Director | 20-Nov-2014 | Current |
| Chunilal Prajapati | Director | 26-Dec-2016 | Current |
| Lalita Prajapati | Director | 26-Dec-2016 | Current |
Financial Performance of L T & L Pharma.
L T & L Pharma Private Limited, for the financial year ended 2016, experienced significant growth in revenue, with a 210.34% increase. The company also saw a substantial fall in profitability, with a 113.82% decrease in profit. The company's net worth observed a substantial decline by a decrease of 443.57%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of L T & L Pharma?
In 2017, L T & L Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 07 Mar 2018 | ₹1.00 Cr | Open |
How Many Employees Work at L T & L Pharma?
L T & L Pharma has a workforce of 0 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of L T & L Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped L T & L Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
